Diabetic Postmenopausal Women Research Articles

Association of periodontitis with serum osteoprotegerin level in type 2 diabetic postmenopausal women.

To evaluate the association of periodontitis with serum osteoprotegerin level according to glycaemic state in postmenopausal type 2 diabetic women. The case-control study was conducted from June 2019 to May 2020 at the National Diabetes Centre, Mustansiriyah University, Baghdad, Iraq, and comprised postmenopausal diabetic women with good glycaemic control in group A, diabetic women with poor glycaemic control in group B, and non-diabetic healthy controls in group C. Participants were inducted by using the consecutive sampling technique. Assessment of periodontitis was done by measuring probing pocket depth, gingival recession and clinical attachment level. The ratio between serum osteoprotegerin level and glycated haemoglobin was calculated for all the subjects. Data was analysed using SPSS 24. Of the 150 subjects, 57(38%) were in group A with mean age 57.39±5.89 years, 43(28.7%) were in group B with mean age 58.91±4.95 years, and 50(33.3%) were in group C with mean age 54.92±4.62 years. Probing pocket depth, clinical attachment level and serum osteoprotegerin exhibited higher values in groups A and B compared to group C, and in group B compared to group A (p<0.001). There was a significant positive correlation between Probing pocket depth and serum osteoprotegerin in all groups (p<0.05). Periodontal parameters and serum osteoprotegerin level were significantly higher in diabetic women, especially in those with poor glycaemic control, than in healthy controls, and serum osteoprotegerin level showed a significant positive correlation with probing pocket depth in all the studied groups.

Prevalence of vertebral fractures and associated factors in thai diabetic postmenopausal women

T2DM (Type 2 Diabetes Mellitus) patients with vertebral fractures have a higher mortality rate than non-DM (nondiabetic patients). However, the prevalence of vertebral fractures in the Asian diabetic population is not well established. Moreover, despite an apparent increase in fracture risk in patients with diabetes, Asian countries have provided contradictory data demonstrating that bone mineral density (BMD) varies significantly in T2DM patients. The aim of this study was to examine and compare the prevalence of vertebral fractures and osteoporosis, as well as BMD and the FRAX score, between individuals with and without T2DM and assess the association of these factors with vertebral fractures. Postmenopausal Thai women attending diabetic and health check-up clinics were recruited. BMD at the lumbar spine, total hip, and femoral neck was measured via dual-energy X-ray absorptiometry. A morphometric vertebral fracture (VF) was defined by a lateral thoracolumbar (T-L) X-ray radiograph. The Fracture Risk Assessment Tool (FRAX) was used to calculate the 10-year probabilities of hip and major osteoporotic fracture (MOF), which were calculated on the basis of the Thai FRAX model. A total of 435 participants were recruited, including 145 postmenopausal women with T2DM and 290 non-DM individuals. T2DM patients had a significantly greater BMI (p = 0.006) and BMD at the femoral neck (p = 0.024) and total hip (p = 0.017), but there was no significant difference in the FRAX score, including the 10-year probability of hip fracture or MOF, either with or without BMD, between individuals with and without T2DM. The prevalence of osteoporosis in non-DM women was significantly higher at the femoral neck (OR = 0.56, 95% CI: 0.34 to 0.93, p = 0.029) but comparable at the lumbar spine. Individuals with T2DM had a significantly higher rate of vertebral fractures, particularly those involving two or more levels, than those without T2DM. Diabetes was significantly associated with \\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\:\\ge\\:$$\\end{document}2 VF (OR = 3.83, 95% CI: 1.77 to 8.28, p = 0.001), and the association remained unchanged after controlling for other clinical factors (adjusted OR = 3.72, 95% CI 1.70–8.15; p = 0.001). Our study demonstrated a greater prevalence of multiple (\\documentclass[12pt]{minimal} \\usepackage{amsmath} \\usepackage{wasysym} \\usepackage{amsfonts} \\usepackage{amssymb} \\usepackage{amsbsy} \\usepackage{mathrsfs} \\usepackage{upgreek} \\setlength{\\oddsidemargin}{-69pt} \\begin{document}$$\\:\\ge\\:$$\\end{document} two levels) VFs in women with T2DM than in non-DM controls.

Bone Mineral Density and the Risk of Type-2 Diabetes in Postmenopausal Women: rs4988235 Polymorphism Associated with Lactose Intolerance Effects.

The study was conducted among 607 female patients in the postmenopausal period in whom bone densitometry and vitamin-D3 levels were assayed and genotyping of the rs4988235 polymorphism of MCM6 gene was performed. The obtained results were analysed for the presence of T2DM, obesity surrogates, medical data, and past medical history. The distribution of genotype frequencies was consistent with the Hardy-Weinberg equilibrium (p > 0.050). Postmenopausal women with the GG homozygote of rs4988235 polymorphism consumed significantly less calcium (dairy), which was probably related to the observed lactose intolerance. The GG homozygote of women with rs4988235 polymorphism was significantly more likely to have T2DM relative to the A allele carriers (p = 0.023). GG homozygotes had significantly lower femoral-vertebral mineral density despite the significantly more frequent supplementation with calcium preparations (p = 0.010), vitamin D (p = 0.01), and anti-osteoporotic drugs (p = 0.040). The obtained results indicate a stronger loss of femoral-neck mineral density with age in the GG homozygotes relative to the A allele carriers (p = 0.038). In the population of women after menopause, the carriage of the G allele of rs4988235 polymorphism of the MCM6 gene, i.e., among the patients with lactose intolerance, significantly increased the risk of developing T2DM and the loss of BMD.

Relation between serum sclerostin and CTRP3 levels and bone mineral density in diabetic postmenopausal women

BackgroundOsteoporosis (OP) is a common finding in diabetic patients especially high-risk populations such as postmenopausal women. Sclerostin is a glycoprotein chiefly secreted by mature osteocytes and is considered a main regulator of bone formation. The C1q/TNF-Related Protein 3 (CTRP3) was found to be significantly associated with OP in postmenopausal women. The effect of type 2 diabetes mellitus (T2DM) on sclerostin and CTRP3 levels in postmenopausal women is rarely investigated. The present study aimed to assess the impact of T2DM on sclerostin and CTRP3 levels and their relation to OP in postmenopausal women.MethodsThe study included 60 postmenopausal women with T2DM and 60 age-matched postmenopausal non-diabetic women. Bone mineral density (BMD) was assessed using dual energy X-ray absorptiometry (DEXA). Serum levels of sclerostin and CTRP3 were assessed using enzyme-linked immunosorbent assay (ELISA) technique.ResultsDiabetic group expressed significantly higher serum levels of sclerostin when compared with non-diabetic group (110.0 ± 29.0 versus 51.5 ± 23.2 ng; p < 0.001). Oppositely, CTRP3 were significantly lower in the diabetic group (3.5 ± 3.5 versus 9.9 ± 3.7 ng/ml, p < 0.001). Multivariate logistic regression analysis identified HbA1c levels [OR (95% CI): 0.49 (0.26–0.93), p = 0.028], sclerotin levels [OR (95% CI): 1.06 (1.0-1.012), p = 0.041] and CTRP3 levels [OR (95%) CI: 1.64 (1.0-2.68), p = 0.047] as significant predictors of OP in diabetic patients.ConclusionsSclerostin and CTRP3 levels are involved in OP in postmenopausal diabetic patients.

Angiogenic Effects of Aerobic Training and Royal Jelly Consumption with Emphasis on the Role of miR-126 and miR-210 in the Aortic Artery of Ovariectomized Diabetic Rats

Background: Cardiovascular complications in postmenopausal diabetic women are significantly higher than in their healthy peers. Although the beneficial effects of exercise interventions and consumption of foods rich in antioxidants on angiogenesis have been established, the synergistic effects of exercise training and royal jelly (RJ) consumption on angiogenesis in ovariectomized diabetic patients are still not well understood. Objectives: This study investigated the angiogenic effects of aerobic training (AT) and royal jelly (RJ) consumption, with an emphasis on the role of miR-126 and miR-210 in the aortic artery of ovariectomized diabetic (OVXD) rats. Methods: Thirty female OVXD rats were divided into five groups: OVXD control, Sham (Sh), RJ, AT, and AT + RJ. Additionally, six healthy rats were selected as the healthy control group (HC) to evaluate the effects of modeling on variables. Groups 4 and 5 underwent aerobic training for eight weeks, five sessions per week, with an intensity of 55 - 75% of VO2max. Groups 3 and 5 received 100 mg/kg/day of RJ. A one-way ANOVA test was used to analyze VEGF, eNOS, miR-126, and miR-210 (α = 0.05). Results: Vascular endothelial growth factor, eNOS, and miR-210 levels in the AT, RJ, and AT + RJ groups were higher than in the OVXD group (P ≤ 0.05). Although miR-126 levels in the RJ and AT + RJ groups were higher than in the OVXD group (P ≤ 0.05), the effects of AT and RJ separately on increasing VEGF and eNOS were more favorable than the combined effect of AT + RJ. Conclusions: While both AT and RJ supplementation individually increase markers of vascular angiogenesis, the simultaneous effects of these two interventions seem to moderate this mechanism.

Supplementation with Highly Standardized Cranberry Extract Phytosome Achieved the Modulation of Urinary Tract Infection Episodes in Diabetic Postmenopausal Women Taking SGLT-2 Inhibitors: A RCT Study.

Urinary tract infections (UTIs) are the most common bacterial infections in postmenopausal women, and women with diabetes are possibly at a higher risk. The aim of this study is to evaluate the potential benefit on the prevention of UTI episodes, assessed by urinalysis and urine culture (primary outcome) after two, four and six months, of daily oral dietary supplement (120 mg highly standardized cranberry extract phytosome), compared to placebo, in diabetic postmenopausal women taking SGLT-2 inhibitors. Forty-six subjects (mean age 72.45 ± 1.76) completed the study (23 placebo/23 supplement). Considering UTI episodes, during the six-month supplementation period, an increase of 1.321 (95% CI: -0.322; 2.9650) was observed in the placebo group, while it remained at a steady value of 0.393 (95% CI: -4.230; 5.016) in the supplemented group. Regarding UTI episodes, in both groups, interaction between times for supplementation was statistically significant (p = 0.001). In particular, at follow-up 4, 9% of the placebo group showed infection versus only 3% with cranberry supplementation. Glycaemia and glycated hemoglobin values (secondary outcomes) were not modified at the end of six months with respect to the basal values in both groups, as expected. While in terms of quality of life per the SF-12 health questionnaire, there were no differences between the two groups, an improvement in SF-12 quality of life was observed in both groups (six months vs. basal). In conclusion, highly standardized cranberry extract phytosome supplementation reduced UTI recurrence.

Follicle-Stimulating Hormone and Diabetes in Postmenopausal Women: A Systematic Review and Meta-Analysis.

The co-occurrence of hormonal changes during menopause and the risk of cardio-metabolic disorders has been well studied. We explored the association of circulating levels of follicle-stimulating hormone (FSH) with diabetes (DM) among postmenopausal women. In this systematic review and meta-analysis, the search was performed in PubMed, Scopus, Web of Sciences, Epistemonikos, and Cochrane Library up to September 2023. Risk of bias was assessed by Newcastle-Ottawa Quality Assessment Scale. Pooled estimates of mean differences in FSH levels were compared between postmenopausal women with and without DM. Correlations between FSH and fasting blood glucose (FBG)/insulin/homeostatic model assessment for insulin resistance (HOMA-IR) as well as pooled effect sizes with their 95% CIs for risk of DM were calculated. In this study, 14 articles, including 7878 postmenopausal women, met eligibility criteria. Most of the included studies had a low/moderate risk of bias. Women with DM had significantly lower FSH levels than those without DM (standardized mean difference [SMD] -0.751 [95% CI, -1.129 to -.372], I2 = 82.46%, n = 1416). The pooled effect size for diabetes was 0.861 (95% CI, 0.740-1.001; I2 = 80.11%). The pooled risk estimate for DM based on the categorical FSH levels (high vs low) was (HR = 0.550; 95% CI, 0.356-0.850, I2 = 0). The significant inverse correlation was found between FSH levels and glycemic parameters: FBG (r= -0.285 [95% CI -0.441 to -0.113]; n = 1229), HOMA-IR (r = -0.241[-0.378 to -0.0924]; n = 1229) and insulin (r = -0.337 [-0.434 to -0.232]; n = 959)]. There were no statistically significant differences between estradiol levels among diabetic and nondiabetic groups; however, the SMD for luteinizing hormone was similar to that reported for FSH. The available data indicated an indirect association between FSH levels and glucose disturbances among postmenopausal women, notwithstanding heterogeneity among included studies, and the complexity of various influential factors needs to be considered. Further efforts should be made to clarify the underlying mechanisms.

GPER activation attenuates cardiac dysfunction by upregulating the SIRT1/3-AMPK-UCP2 pathway in postmenopausal diabetic rats.

Postmenopausal diabetic women are at higher risk to develop cardiovascular diseases (CVD) compared with nondiabetic women. Alterations in cardiac cellular metabolism caused by changes in sirtuins are one of the main causes of CVD in postmenopausal diabetic women. Several studies have demonstrated the beneficial actions of the G protein-coupled estrogen receptor (GPER) in postmenopausal diabetic CVD. However, the molecular mechanisms by which GPER has a cardioprotective effect are still not well understood. In this study, we used an ovariectomized (OVX) type-two diabetic (T2D) rat model induced by high-fat diet/streptozotocin to investigate the effect of G-1 (GPER-agonist) on sirtuins, and their downstream pathways involved in regulation of cardiac metabolism and function. Animals were divided into five groups: Sham-Control, T2D, OVX+T2D, OVX+T2D+Vehicle, and OVX+T2D+G-1. G-1 was administrated for six weeks. At the end, hemodynamic factors were measured, and protein levels of sirtuins, AMP-activated protein kinase (AMPK), and uncoupling protein 2 (UCP2) were determined by Western blot analysis. In addition, cardiac levels of oxidative stress biomarkers were measured. The findings showed that T2D led to left ventricular dysfunction and signs of oxidative stress in the myocardium, which were accompanied by decreased protein levels of Sirt1/2/3/6, p-AMPK, and UCP2 in the heart. Moreover, the induction of the menopausal state exacerbated these changes. In contrast, treatment with G-1 ameliorated the hemodynamic changes associated with ovariectomy by increasing Sirt1/3, p-AMPK, UCP2, and improving oxidative status. The results provide evidence of the cardioprotective effects of GPER operating through Sirt1/3, p-AMPK, and UCP2, thereby improving cardiac function. Our results suggest that increasing Sirt1/3 levels may offer new therapeutic approaches for postmenopausal diabetic CVD.

Asprosin is a Reliable Predictor of Osteoporosis in Type 2 Diabetic Postmenopausal Women: A Case–Control Study

Asprosin is a Reliable Predictor of Osteoporosis in Type 2 Diabetic Postmenopausal Women: A Case–Control Study

Adverse pregnancy outcomes and risk of type 2 diabetes in postmenopausal women

Although gestational diabetes mellitus and delivering high-birthweight infants are known to predict a higher risk of future type 2 diabetes mellitus, the association of hypertensive disorders of pregnancy and other adverse pregnancy outcomes with type 2 diabetes mellitus is not well established. This study aimed to examine the associations between different types of adverse pregnancy outcomes and incident type 2 diabetes mellitus among postmenopausal women. The Women's Health Initiative, a nationwide cohort of postmenopausal women, collected self-reported history of adverse pregnancy outcomes, including gestational diabetes mellitus, hypertensive disorders of pregnancy, preterm birth, and delivering low- birthweight (<2500 g) or high-birthweight (>4500 g) infants. Participants were followed up annually for self-reported incident type 2 diabetes mellitus treated with medication from baseline (1993-1998) to March 2021. This study used logistic regression to examine the associations of any and individual adverse pregnancy outcomes with diabetes mellitus. Stratified analyses were performed to assess effect modification by body mass index, race and ethnicity, education, parity, breastfeeding, and age at first birth. This analysis included 49,717 women without a history of diabetes mellitus at enrollment who had a least 1 pregnancy and responded to the questionnaire about adverse pregnancy outcomes. After adjusting for body mass index, demographic, lifestyle, and reproductive factors, gestational diabetes mellitus (odds ratio, 2.26; 95% confidence interval, 1.94-2.63), high birthweight (odds ratio, 1.30; 95% confidence interval, 1.18-1.44), and hypertensive disorders of pregnancy (odds ratio, 1.18; 95% confidence interval, 1.08-1.30) were independently associated with higher odds of type 2 diabetes mellitus, whereas preterm birth and low birthweight were not associated with diabetes mellitus risk. A history of ≥2 adverse pregnancy outcomes was associated with higher odds of type 2 diabetes mellitus (odds ratio, 1.55; 95% confidence interval, 1.28-1.88). This study further observed higher odds of type 2 diabetes mellitus (odds ratio, 3.69; 95% confidence interval, 2.38-5.70) among women with a history of both gestational diabetes mellitus and hypertensive disorders of pregnancy than those without any adverse pregnancy outcomes. Postmenopausal women with a history of gestational diabetes mellitus, those delivering high-birthweight infants, or those with hypertensive disorders of pregnancy are at risk of future type 2 diabetes mellitus. In addition, women with ≥2 conditions had an augmented risk and might be prioritized for screening and prevention efforts for type 2 diabetes mellitus.

Insulin therapy combined or not with metformin is associated to a reduced bone mineral density and content in type 2 diabetic postmenopausal women

Anti-diabetic drugs may have negative, positive or neutral effect on bone health. The aim of this study was to compare the effect of combined treatment of metformin and insulin, metformin monotherapy and insulin monotherapy on Bone Mineral Density (BMD)

The Association between Postmenopausal Hormone Use and Risk of Type 2 Diabetes in Postmenopausal

Background: 100 postmenopausal women were examined for their usage of postmenopausal hormones and their risk of Type 2 diabetes. The findings demonstrated a significant association between the use of postmenopausal hormones and the incidence of Type 2 diabetes (odds ratio, 2.7; 95% confidence range, 1.4-5.1; P 0.001). Compared to women who did not take postmenopausal hormone treatment, those who did had a nearly 3-fold increased risk of diabetes. So, this research showed how crucial it is to consider postmenopausal hormones as a risk factor for Type 2 diabetes in postmenopausal women. Objectives: This study's main goal was to determine postmenopausal hormone usage and the likelihood of developing Type 2 diabetes in 100 postmenopausal women at the Hayatabad Medical Complex in Peshawar, Pakistan; the specific goals were to define the features of the research population, evaluate the relationship between diabetes and postmenopausal hormone usage, and pinpoint risk factors for Type 2 diabetes in postmenopausal women. Methods: The research was carried out at the Hayatabad Medical Complex's Department of Endocrinology in Peshawar, Between January 2022 And January 2023. The research's participants included 100 postmenopausal women, aged 50 to 65, from the same institution who had been on postmenopausal hormone treatment for at least three months before the trial. Through blood tests (fasting glucose and hemoglobin A1c), participants' risk of developing diabetes was evaluated. Additionally evaluated were other variables, including medical history, body mass index, and lifestyle choices that can influence the chance of getting Type 2 diabetes. Data were gathered using a semi-structured questionnaire, and descriptive statistics and logistic regression were used to analyze the results.

QTC PROLONGATION, AN EARLY PREDICTOR OF CARDIOVASCULAR AUTONOMIC NEUROPATHY (CAN) IN POSTMENOPAUSAL DIABETIC WOMEN

To evaluate QTc interval in postmenopausal diabetic women in predicting cardiovascular autonomic neuropathy (CAN). A comparative cross-sectional study was conducted in the Cardiology Department of CMH Lahore and Sir Ganga Ram Hospital, Lahore, from April 2022- April 2023. A total of 80 women were included in the study, which was categorized into 40 pre and 40 postmenopausal women. Both groups were further divided into 20 diabetic and 20 non-diabetic women. A cut-off of 3-5 years was selected for natural menopause and 5-7 years for the available duration of type 2 diabetes. Blood samples were taken to determine serum estradiol levels in all 4 groups. Autonomic neuropathy was assessed by corrected QT interval (QTc), heart rate variability (HRV), Valsalva Ratio (VR), and resting heart rate (RHR). All variables were compared among groups by using SPSS version 20.0. Serum estradiol levels were significantly lowered in postmenopausal as compared to premenopausal women (p&lt;0.001). QTc was significantly different (p=0.001) among all four groups. A statistically significant difference was found between premenopausal diabetic and postmenopausal diabetic groups (p=0.001) and between women of premenopausal non-diabetic and postmenopausal diabetic groups (p=0.003). Differences in RHR (p=0.840), HRV (p=0.084), and VR (p=0.129) were statistically nonsignificant among all four groups. A QTc prolongation is an important tool in investigating cardiac autonomic neuropathy (CAN) predisposition in postmenopausal diabetic women. Therefore, assessment of QTc prolongation could aid in early diagnosis of CAN in postmenopausal diabetic women.

Micronutrient deficiencies and functional disorders of postmenopausal diabetic women

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Abstract #1375340: Correlation of Follicle Stimulating Hormone and Luteinizing Hormone Levels with HbA1c in Post-Menopausal Females

Menopause in female is a normal physiological process however, it is also a well-established risk factor for CVD and osteoporosis. Few studies suggest that low FSH is associated with adiposity and diabetes in post-menopausal women. Aim of this study was to explore correlations of follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels with HbA1c level in post-menopausal females. The study was conducted at of Dr. S.N. Medical College, Jodhpur, India. Otherwise healthy postmenopausal women attending hospital for preventive health checkup were included in study. Postmenopausal status was confirmed by the absence of menses for at least 12 months. Known case of T2D/T1D, subjects on hormone replacement therapy, acutely sick were excluded from study. The baseline fasting blood samples were collected. Samples was assayed for FSH, LH, HbA1c and standard biochemical profile (glucose, lipid profile, Live function tests and renal function tests) using standard methods. The participants were classified as having diabetes or prediabetes using ADA criterias. Total 229 postmenopausal women were enrolled. Mean age of subjects was 63.2±9.9 years. Mean Hba1c was 6.2±1.4 gm% and subjects were further divided in to non-diabetes (68/229), prediabetes (104/229) and diabetes group (57/229) according to Hba1c levels. Mean LH was 25.8±15.6, FSH was 61.1±30.1 and LH/FSH ratio was 0.47±0.35. Mean LH was 31.4±15.8, 26.0±16.3, 19.5±12.6 in non-diabetes, prediabetes and diabetes group respectively. Mean FSH was 75.9±29.3, 59.6±27.6, 46.9±29.0 in non-diabetes, prediabetes and diabetes group respectively. The LH and FSH values in non-diabetes and diabetes group were statistically significant (p<0.01). In this study low FSH and LH levels were associated with higher level of HbA1c and increased risk of T2D.

Relation between aortic elasticity parameters and SYNTAX score in postmenopausal diabetic women

BackgroundPostmenopausal women are at increased risk of coronary artery disease (CAD). Diabetes Mellitus is a major risk factor for CAD. The stiffening of the aorta is associated with increased cardiovascular morbidity and mortality. We aimed to investigate the relation of aortic elasticity parameters to CAD severity assessed by SYNTAX score (SS) in diabetic postmenopausal women. The study prospectively included 200 consecutive diabetic postmenopausal women with CAD who underwent elective coronary angiography. Patients were classified into 3 groups based on SS, low-SS ≤ 22, intermediate-SS ≥ 23– ≤ 32, and high-SS ≥ 33. Echocardiographic aortic elasticity parameters, including aortic stiffness index (ASI), aortic strain (AS) (%) and aortic distensibility (AD) were obtained in all patients.ResultsPatients in the high SS group were older age and had a higher aortic stiffness. After adjusting different co-variates AD, AS, and ASI could be used as independent predictors of high SS with the following P-values (0.019, 0.016 and 0.010) and cut-off values (2.5, 3.6 and 2.9), respectively.ConclusionsIn diabetic postmenopausal women, the simple echocardiography-derived aortic elasticity parameters might predict the severity and complexity of angiographic coronary lesions assessed by the SS.

Diagnostic markers of insulin resistance to discriminate between prediabetes and diabetes in menopausal women.

Menopause is an important transition period in a woman's reproductive life during which hormonal changes occur, resulting in an increased risk of cardiovascular disease and type 2 diabetes. In this study, we assessed the possibility of using surrogate measures of insulin resistance (IR) to predict the risk of insulin resistance in perimenopausal women. The study involved 252 perimenopausal women living in the West Pomeranian Voivodeship. The methods employed in this study were diagnostic survey based on the original questionnaire, anthropometric measurement, and laboratory tests performed to determine the levels of selected biochemical parameters. In the entire study population, the highest area under the curve was found for the homeostasis model assessment-insulin resistance (HOMA-IR) and quantitative insulin sensitivity check index (QUICKI). Triglyceride-glucose index (TyG index) showed a higher diagnostic value as a distinction tool between prediabetes and diabetes in perimenopausal women than the other markers. HOMA-IR significantly positively correlated with fasting blood glucose (r = 0.72; p = 0.001), glycated hemoglobin (HbA1C, r = 0.74; p = 0.001), triglycerides (TG, r = 0.18; p < 0.005), and systolic blood pressure (SBP, r = 0.15; p= 0.021), and negatively with high-density lipoprotein (HDL, r = -0.28; p = 0.001). QUICKI negatively correlated with fasting blood (r = -0.051; p = 0.001), HbA1C (r = -0.51; p = 0.001), TG (r = -0.25; p = 0.001), low-density lipoprotein (LDL, r = -0.13; p= 0.045), and SBP (r = -0.16; p = 0.011), and positively with HDL (r = 0.39; p = 0.001). Anthropometric and cardiometabolic parameters were found to significantly correlate with IR markers. HOMA-beta, the McAuley index (McA), visceral adiposity index (VAI), and lipid accumulation product (LAP) may be useful as predictors of pre-diabetes and diabetes in postmenopausal women.

Assessment of endothelial dysfunction and inflammation in type 2 diabetic postmenopausal women

Objective: Vascular complications in type 2 diabetes mellitus are an important cause of morbidity and mortality. Also, endothelial dysfunction arises with vascular ageing during the postmenopausal period. Our objective in this study was to evaluate inflammation and endothelial function parameters and their possible diagnostic roles in type 2 diabetic postmenopausal patients. Material and Methods: The study was conducted on four groups, including type 2 diabetic premenopausal (n:20), non-diabetic premenopausal (n:20), type 2 diabetic postmenopausal (n:20), and non-diabetic postmenopausal subjects (n:20). Serum endothelin-1 (ET-1), endothelial nitric oxide synthetase (eNOS), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), and chitinase-3-like protein 1 (YKL-40) levels were determined as inflammatory and endothelial function markers using ELISA kits. Results: Serum ET-1, IL-6, and YKL-40 levels were higher in the type 2 diabetic postmenopausal group compared to the non-diabetic premenopausal group (p&lt;0.01, p&lt;0.05, and p&lt;0.01, respectively). ET-1, IL-6, and YKL-40 levels were higher in the type 2 diabetic postmenopausal group compared to the non-diabetic postmenopausal group (p&lt;0.001, p&lt;0.05, and p&lt;0.01 respectively). ROC analysis revealed serum ET-1 (AUC 0.933, sensitivity 87.5%, specificity 85.7%), IL-6 (AUC 0.812, sensitivity 56.3%, specificity 92.8%), and YKL-40 (AUC 0.880, sensitivity 81.2%, specificity 92.8%), as good diagnostic parameters, especially in the type 2 diabetic premenopausal vs. non-diabetic premenopausal cohorts. Conclusion: Serum ET-1, IL-6, and YKL-40 levels were at the highest levels in the 2 diabetic postmenopausal group, and the increase in these markers was remarkable in diabetes compared with menopausal periods. Also, ET-1, IL-6, and YKL-40 were good diagnostic parameters for detecting endothelial function and inflammation in type 2 diabetic postmenopausal and non-diabetic premenopausal cohorts.

Homoeopathic management of diabetes mellitus among post-menopausal women by Helonias dioica: A case series

A sample of 15 cases of post-menopausal diabetic women from OPD of Sarada Krishna Homoeopathic Medical College and Hospital were selected, detailed case taking was done and Helonias Dioica in different potencies was administered as per the directions of 5th and 6th editions of Organon of medicine, including its repetition and dosage. FBS and serum HbA1c levels of the individual were measured on the first visit itself. Advices were given to follow a healthy diet. The cases were followed up for 12 weeks to obtain correct changes in serum HbA1c. FBS was analysed in follow ups of every 2 weeks and the repetition of dose, change in potency/medicine was decided based on the overall condition of the patient. After 3 months, HbA1c level was taken and in about 80% of the cases had their HbA1c levels reduced.

Association of Serum Uric Acid with Diabetes in Premenopausal and Postmenopausal Women-A Prospective Cohort Study in Shanghai, China.

There have been few prospective studies on the association between serum uric acid (SUA) and the risk of diabetes in women, and there have been few large-scale Chinese studies based on menopause to investigate the association. Therefore, the present study aimed to investigate the above relationship in Chinese female adults without diabetes. Methods: Data from 5743 premenopausal women and 11,287 postmenopausal women aged 20−74 years were obtained from the Shanghai Suburban Adult Cohort and Biobank (SSACB) study conducted in China. Cox regression models were applied to evaluate the association between SUA levels and the risk of diabetes. Restricted cubic spline analysis and stratified analysis on the basis of menopausal status were performed to explore the dose−response association between SUA levels and diabetes. Results: Among 17,030 participants, incidence rates of diabetes were 3.44/1000 person-years in premenopausal and 8.90/1000 person-years in postmenopausal women. The SUA levels in postmenopausal women were higher than that in premenopausal women (p < 0.0001). In Cox regression analysis, after adjusting for confounding factors, for each 10 µmol/L increase in SUA levels, the adjusted HR of diabetes was 1.01 (95% CI: 0.97−1.04) in postmenopausal women, and 1.03 (95% CI: 1.01−1.04) in premenopausal women. Compared with the lowest quartile of SUA levels, the HR (95% CI) of diabetes in the highest quartile was 0.99 (0.55−1.79) in premenopausal women and 1.39 (1.07−1.81) in postmenopausal women. Compared with those without hyperuricemia, the HR (95% CI) for diabetes was 1.89 (0.67−5.31) in premenopausal women with hyperuricemia, and 1.55 (1.19−2.02) in postmenopausal women. Moreover, restricted cubic splines models showed that there was a linear relationship between SUA levels and diabetes risk in premenopausal (p for nonlinear = 0.99) and postmenopausal women (p for nonlinear = 0.95). Furthermore, the restricted cubic spline graph showed that the risk of diabetes in postmenopausal women increased with an increase in SUA levels (p = 0.002). Conclusions: In a cohort of Chinese adult women, SUA levels are associated with diabetes risk in postmenopausal women, but this association was not observed in premenopausal women.